Silent cerebral microvascular disease and longitudinal risK of cognitive decline in Atrial Fibrillation study

Trial Profile

Silent cerebral microvascular disease and longitudinal risK of cognitive decline in Atrial Fibrillation study

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2017

At a glance

  • Drugs Edoxaban (Primary)
  • Indications Atrial fibrillation
  • Focus Pharmacodynamics
  • Acronyms SKAF Study
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 04 Oct 2017 New trial record
    • 02 Oct 2017 Planned initiation date changed from 1 Oct 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top